Entrada (TRDA) Director Bernhardt G. Zeiher Receives 19,000-Share Award

What Happened Bernhardt G. Zeiher, a director of Entrada Therapeutics, was granted a derivative award on 2026-06-10 covering 19,000 shares. The filing reports the acquisition at $0.00, indicating a grant of an option (not an open-market purchase or sale). No cash value or immediate sale was reported in the Form 4.

Key Details

• Transaction date: 2026-06-10; Form 4 filed: 2026-06-12 (filed within the typical 2-business-day window).
• Security: Derivative (option) covering 19,000 shares; acquisition price reported as $0.00.
• Vesting: The option vests on the earlier of (i) the one-year anniversary of June 10, 2026 or (ii) the issuer’s next annual meeting of stockholders (per footnote).
• Shares owned after the transaction: Not specified in the filing.
• Filing timeliness: Timely (no late-filing indication).

Context This was an award of an option to a board director with time-based vesting; it does not represent an open-market buy or sale. Such grants are common for compensating directors and do not by themselves indicate the insider sold or immediately monetized shares.